Managing the Allergic Flare: Clinical Strategies & Novel Options With Dr. Griffin

When an allergic flare strikes, fast and effective relief is critical—not just for patient comfort but to prevent chronic skin damage and infection as well. In this podcast episode, dermatology specialist Dr. Joya Griffin dives into how to diagnose the source of pruritus, how to choose between starting symptomatic treatment or performing additional diagnostics, and how to integrate Janus kinase (JAK) inhibitors into the multimodal management of allergic disease in dogs.

Sponsored by Elanco

Contact us:

• Podcast@instinct.vet

Where to find us:

• Website: CliniciansBrief.com/Podcasts
• YouTube: Youtube.com/@clinicians_brief
• Facebook: Facebook.com/CliniciansBrief
• LinkedIn: LinkedIn.com/showcase/CliniciansBrief/
• X: @cliniciansbrief
• Instagram: @clinicians.brief

The Team:

• Beth Molleson, DVM - Host
• Sarah Pate - Producer & Project Manager, Brief Studio
• Taylor Argo - Podcast Production & Sound Editing

INDICATIONS

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning. For full prescribing information call 1-888-545-5973 or visit http://www.elancolabels.com/us/zenrelia WARNING: INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of an inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to infections, including adenoviral hepatitis and pancreatitis. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert. For full prescribing information see package insert.